The Drp1 inhibitor DRP1i2 confers cardioprotection against doxorubicin-induced cardiotoxicity
It is demonstrated that DRP1i2 confers cardioprotection while maintaining anticancer efficacy via modulation of Drp1-dependent mitochondrial dynamics, supporting mitochondrial fission as a targetable pathway to mitigate doxorubicin-induced cardiotoxicity.